CLINICAL TRIALS

Leukemia (AML) Clinical Trials in Colorado

10+ recruiting Leukemia (AML) trials in Colorado, sourced from ClinicalTrials.gov.

Informational only. Not medical advice. Always consult a qualified healthcare professional.
Data sourced from ClinicalTrials.gov (NLM/NIH).

ACTIVE NOT RECRUITINGPhase 3

Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

This phase III trial compares hematopoietic (stem) cell transplantation (HCT) using mismatched related donors (haploidentical \[haplo\]) versus matched unrelated donors (MUD) in treating children, adolescents, and young

NCT05457556 · Aurora
RECRUITINGPhase 1

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

This screening and multi-sub-study Phase 1b/2 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)." The specific subtyp

NCT03013998 · Denver
ACTIVE NOT RECRUITINGPhase 1

Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia

This phase I trial studies the side effects, best dose of flotetuzumab and how well it works in treating patients with acute myeloid leukemia (AML) that has come back (recurrent) or has not responded to treatment (refrac

NCT04158739 · Aurora
RECRUITINGPhase 1

Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia

This is an open label, phase 1 study for AML subjects with relapsed or refractory disease or subjects in morphologic remission with MRD+ after first line therapy with venetoclax+HMA. A preliminary dose-finding cohort wil

NCT06429449 · Aurora
RECRUITINGPhase 1

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation. The first po

NCT02074839 · Aurora
ACTIVE NOT RECRUITING

Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events

Prospective determination of the clinical utility of measurable residual disease (MRD) testing for relapse and survival of patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantati

NCT05224661 · Aurora
RECRUITINGPhase 1

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN

NCT05476770 · Denver
RECRUITINGPhase 1

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

This is a Phase 1b open-label, multicenter, dose-escalation and dose-optimization study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor efficacy of eganelisib a

NCT06533761 · Aurora
ACTIVE NOT RECRUITINGPhase 1

A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia

People with acute myeloid leukemia (AML) are usually treated with chemotherapy. Some people with AML have a changed FLT3 gene which causes leukemia cells to grow faster. Therefore, chemotherapy is less suitable to treat

NCT05520567 · Denver
ACTIVE NOT RECRUITINGPhase 2

Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation

This phase II trial studies the side effects of enasidenib and sees how well it works in treating pediatric patients with acute myeloid leukemia that has come back after treatment (relapsed) or has been difficult to trea

NCT04203316 · Aurora

RECOMMENDED RESOURCES FOR LEUKEMIA (AML)

🛡️

GoHealth

Medicare Specialist

Compare Medicare Advantage and Supplement plans with a licensed advisor. Many patients with chronic conditions qualify for $0-premium plans with extra benefits.

Check Your Coverage →

Clinicals AI may earn a referral fee. At no cost to you.

COMMON QUESTIONS

Are there Leukemia (AML) clinical trials in Colorado?

Yes. Clinicals AI lists 10+ recruiting Leukemia (AML) trials in Colorado sourced from ClinicalTrials.gov. Browse them above or search across all states.

How do I qualify for a Leukemia (AML) trial in Colorado?

Eligibility varies by study. Most trials require a confirmed Leukemia (AML) diagnosis, fall within a specific age range, and may have restrictions based on prior treatments. Review each listing's criteria and submit a contact request for more details.

Are Leukemia (AML) clinical trials free to join?

Most trials cover the investigational treatment and all study-related visits. Some also offer compensation for travel and time. Always confirm the cost structure with the trial coordinator before enrolling.